The Medical Letter on Drugs and Therapeutics
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
Antiviral Drugs for Seasonal Influenza 2014-2015
Revised 1/7/15: Since publication of the Antiviral Drugs for Seasonal Influenza article, peramivir has been approved. We have updated the table to reflect this.

Antiviral drugs can be used for treatment of influenza and as an adjunct to influenza vaccination1 for prophylaxis. Frequently updated information on influenza activity and antiviral resistance is available from the CDC at

NEURAMINIDASE INHIBITORS — Oseltamivir (Tamiflu), which is taken orally, and zanamivir (Relenza), which is inhaled, can be used for chemoprophylaxis and treatment of influenza. When used for prophylaxis after exposure to susceptible strains of seasonal influenza A or B viruses, they have generally been about 70-90% effective.2

In patients with mild illness caused by a susceptible strain of influenza, starting treatment with a neuraminidase inhibitor within 48 hours after the onset of illness can ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1457
 Downloadable, electronic issue - $45

Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian